---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-200629"
form_type: "8-K"
ticker: "TECX"
cik: "0001681087"
company_name: "Tectonic Therapeutic, Inc."
filed_at: "2024-08-14T23:59:59+00:00"
generated_at: "2026-05-31T09:21:52.119618+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Tectonic reports Q2 net loss $12.7M; cash $185.1M; TX45 Phase 2 trial open

## Summary
- Net loss of $12.7M for Q2 2024 vs $10.5M in Q2 2023; R&D expenses $7.1M.
- Cash and cash equivalents $185.1M as of June 30, providing runway into mid-2027.
- TX45 Phase 2 APEX trial for PH-HFpEF open for screening; first dosing expected Sept 2024.
- Closed reverse merger with AVROBIO in June 2024, with concurrent $130.7M private placement.
- Appointed Dan Lochner as CFO in June 2024.

## SEC filing metadata
- accession: 0001193125-24-200629
- form_type: 8-K
- ticker: TECX
- cik: 0001681087
- company_name: Tectonic Therapeutic, Inc.
- filed_at: 2024-08-14T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1681087/000119312524200629/0001193125-24-200629-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1681087/000119312524200629/d838115d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-200629
- JSON: https://secwatch.observer/filing/0001193125-24-200629.json
- Plain text: https://secwatch.observer/filing/0001193125-24-200629.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.